Duke-FDA Coalition Names C3 Board Chair to Clinical Trial Initiative

Posted by Judi Sohn on May 12th, 2008

The Clinical Trials Transformation Initiative (CTTI), a growing, broad-based coalition of organizations dedicated to modernizing the way clinical trials are conducted in the United States, has named a 12-member Executive Board that will oversee its activities.

Founded by the U.S. Food and Drug Administration (FDA) and Duke University as a public-private partnership, CTTI seeks to improve the quality and efficiency of clinical trials. CTTI was formed in the wake of growing frustration among patients, consumers, the academic community and industry over the difficulty of conducting high-quality clinical trials in a timely manner that could produce information physicians need to define optimal treatments for their patients.

This board comprises leading figures in government, academia, industry (pharmaceutical, biotechnology, device and contract research) and patient advocacy.

C3 Board Chair Nancy Roach has been named a member of the CTTI Executive Board as the only representative of the patient advocacy community.

Comments

Jo-Ellen

May 28, 2008 at 5:05pm

Who is more able than Nancy to take on this important responsibility? Thank you, Nancy, for continuing to fill your plate–we need your energy!

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions.

C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond where appropriate.

For the best response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Colorectal Cancer Action Center

Your voice makes a difference. Join us.

Sign Up Now

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe